Pathos AI closes a $237 million Series E led by Bristol Myers Squibb

Pathos AI announced a $237 million Series E at a post-money valuation of about $3 billion, led by Bristol Myers Squibb, to scale its Foundry AI platform and advance a four-asset clinical oncology pipeline (October 23, 2026).